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Abstract 20 
Objective: To compare dosimetrically the stereotactic CyberKnife (CK) therapy and 21 
multicatheter high-dose-rate (HDR) brachytherapy (BT) for accelerated partial breast 22 
irradiation (APBI). 23 
Methods: Treatment plans of twenty-five patients treated with CK were selected and additional 24 
plans using multicatheter HDR BT were created on the same CT images. The prescribed dose 25 
was 6.25/25 Gy in both plans to the target volume (PTV). The dose-volume parameters were 26 
calculated for both techniques and compared. 27 
Results: The D90 total dose of the PTV was significantly lower with CK than with HDR BT, 28 
D90 was 25.7 Gy and 27.0 Gy (p<0.001). However, CK plans were more conformal than BT, 29 
COIN was 0.87 and 0.81 (p=0.0030). The V50 of the non-target breast was higher with CK 30 
than with BT: 10.5% and 3.3% (p=0.0010), while there was no difference in the dose of the 31 
contralateral breast and contralateral lung. Dose to skin, ipsilateral lung and ribs were higher 32 
with CK than with BT: D1 was 20.6 Gy vs. 11.5 Gy (p=0.0018) to skin, 11.4 Gy vs. 9.6 Gy 33 
(p=0.0272) to ipsilateral lung and 18.5 Gy vs. 12.3 Gy (p=0.0013) to ribs, while D0.1 to heart 34 
was lower, 3.0 Gy vs. 3.2 Gy (p=0.0476), respectively. 35 
Conclusions: Multicatheter HDR BT yields more advantageous plans than stereotactic 36 
CyberKnife treatment in accelerated partial breast irradiation, except in terms of dose 37 
conformality and the dose to the heart. There was no difference in the dose of the contralateral 38 
breast and -lung. 39 
Keywords: breast cancer; CyberKnife therapy; multicatheter high-dose-rate brachytherapy; 40 
accelerated partial breast irradiation 41 
 42 
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Introduction 44 
Over the last decades, breast-conserving surgery followed by postoperative radiotherapy 45 
became the standard of care for the treatment of early-stage breast carcinoma [1-2]. Nowadays, 46 
accelerated partial breast irradiation (APBI) is an attractive alternative to conventional whole 47 
breast radiotherapy for selected group of patients [3]. Moreover, it has been demonstrated that 48 
higher doses to the tumour bed significantly reduce the local recurrence rate [4-7]. The number 49 
of techniques and devices used to deliver APBI has increased dramatically in recent decades in 50 
an attempt to create more conformal, homogenous, and reproducible dose distributions as well 51 
as to provide shorter, more convenient treatment schedules. Such as EBRT using 3D conformal 52 
(3D-CRT), intensity-modulated (IMRT) technique or arc-therapy (IMAT) [8], helical 53 
tomotherapy (HT) [9], stereotactic radiotherapy with CyberKnife (CK) [10-14], protontherapy 54 
(PT) [15], as well as high-dose-rate (HDR) or pulsed-dose-rate (PDR) balloon [16] or 55 
multicatheter BT [17] or using Strut Adjusted Volume Implant (SAVI) [18]. All of these 56 
techniques offer equal convenience but differ substantially in dose distribution and treatment 57 
delivery [19]. 58 
While the dosimetric parameters which affect toxicity have been thoroughly 59 
investigated for BT techniques [20-21], and the use of interstitial BT is supported by over ten 60 
years of follow-up data demonstrating excellent local control and minimal long-term toxicity 61 
when established dosimetric guidelines are used for planning [22-26], EBRT is associated with 62 
less available follow-up data, and currently no standardized, evidence-based treatment planning 63 
guidelines exist for this technique. Therefore, a detailed dosimetric analysis comparing the 64 
rapidly developing EBRT techniques to the pivotal BT modality is essential. 65 
In our previous study we compared the dose distributions of 3D-CRT and three different 66 
intensity-modulated APBI technique: step and shoot and sliding window IMRT and IMAT in 67 
40 patients [8]. Goggin et al. [27] compared 3D-CRT and CK with circular (Iris) and multi-leaf 68 
collimators in case of 9 patients. Xu et al. [28] and Rault et al. [29] compared the dosimetry of 69 
CK, 3D-CRT and IMRT plans, while Bonfantini et al. [30] made a dosimetric comparison of 70 
CK, 3D-CRT and IMAT plans. 71 
Khan et al. [31] investigated the dosimetric differences among MammoSite balloon BT, 72 
3D-CRT and IMRT for 15 cases. Previously, we examined the dosimetry of organs at risks 73 
(OARs) in multicatheter HDR BT against IMRT for 34 cases [32]. Hoekstra et al. studied the 74 
long-term risk of secondary cancer calculating Lifetime Attributable Risks using a Rando breast 75 
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phantom in multicatheter HDR BT, 3D-CRT, CK, IMAT and whole breast irradiation (WBI) 76 
[33]. 77 
Recently, stereotactic CyberKnife therapy and interstitial multicatheter high-dose-rate 78 
brachytherapy are considered as the most advantageous APBI techniques in early-stage breast 79 
cancer, at the same time their dosimetric comparison is not available in the literature. At our 80 
institute, both state-of-the art techniques are available. To take the advantage of this situation, 81 
the aim of the present study is a detailed dosimetric comparison of CK treatment and HDR 82 
multicatheter BT for APBI. 83 
Materials and methods 84 
Stereotactic CyberKnife radiotherapy 85 
Twenty-five CK plans of patients with early-stage breast cancer treated at our institute were 86 
included in this study. Selection criteria for treatment were the following: unifocal tumour; 87 
primary tumour size by final pathology <30 mm (pT1); microscopically negative surgical 88 
margins (>2 mm); histologic grade 1–2; pN0 axillary status, age over 50 years, without 89 
extensive intraductalis component or lymph vessel invasion [34]. 90 
CK treatments were performed with non-coplanar fields using CyberKnife M6 linear 91 
accelerator (Accuray, Sunnyvale, CA, USA). Titanium surgical clips were implanted into the 92 
tumour bed during the surgery to help contouring the lumpectomy cavity and defining the 93 
clinical target volume (CTV), and additional 4 fiducial gold markers were placed around the 94 
cavity with US guidance for tracking purpose. The CTV was extended by an isotropic 2 mm 95 
margin to create the planning target volume (PTV), and the fractional prescribed dose was 6.25 96 
Gy. A total of 4 fractions (total dose 25 Gy) were given every consecutive day. For treatment 97 
planning Accuray Precision 1.1 treatment planning system (TPS) (Accuray, Sunnyvale, CA, 98 
USA) was used. The dose was prescribed to the 80−85% isodoses (Fig 1.a). The relative volume 99 
of the PTV receiving at least the prescribed dose (V100) had to be at least 95%. The detailed 100 
description of our treatment method can be found in our previous publication [14]. 101 
Multicatheter brachytherapy 102 
On the CT series made for CK treatment planning, additional plans using virtual interstitial 103 
catheters were created using the same contour set. The CTV was identical to the PTV, and the 104 
prescribed dose was also the same as in CK, 25 Gy in 4 treatment fractions giving 6.25 Gy two 105 
times a day using an HDR Ir-192 radioactive source. HIPO (Hybrid Inverse Planning 106 
5 
 
Optimization) optimisation method was used to achieve the optimal dose distribution, where 107 
the target volume coverage by the reference dose is at least 90%, while keeping the dose non-108 
uniformity ratio (DNR) less than 0.35 (Fig 1.b). For planning the Oncentra Prostate v3.1 TPS 109 
(Elekta Brachytherapy, Veendendaal, The Netherlands) was used. The detailed description of 110 
our treatment method can be found in our previous publications [17,22-25]. 111 
Dosimetric comparison 112 
The absolute and the relative () total dose were calculated for both techniques. The 113 
following dose-volume parameters were used for quantitative evaluation of plans: 114 
D90: the minimum dose delivered to 90% of the PTV; 115 
COIN: conformal index [35]; 116 
V50(non-target breast): the relative volume in percentage of non-target breast 117 
receiving at least the 50% of the prescribed dose; 118 
D1(x), D0.1(x): the minimal dose of the most exposed 1 and 0.1 cm3 of the critical organ 119 
x, 120 
where x: contralateral breast (contralat breast), skin, ipsilateral lung (ipsilat lung), 121 
contralateral lung (contralat lung), heart and ribs. 122 
Wilcoxon Matched Pairs Test was used (Statistica 12.5, StatSoft, Tulsa, OK, USA) to 123 
compare dose-volume parameters of CK and HDR BT techniques. 124 
Results 125 
The mean volume of the CTV and PTV was 51.1 cm3 (27.0-81.5 cm3) and 71.6 cm3 126 
(41.1-105.6 cm3). The ratio of the CTV to the whole breast volume was 0.09 (0.05-0.19). Eleven 127 
patients had tumour in her left breast and fourteen in the right one. 128 
We found that D90 total dose of the PTV was significantly lower with CK than with 129 
HDR BT, it was 25.7 Gy and 27.0 Gy (p<0.001). However, CK plans were more conformal 130 
than BT, the COIN was 0.87 and 0.81 (p=0.0030), respectively. 131 
In our comparison, the V50 of the non-target breast was higher with CK than with BT: 132 
10.5% and 3.3% (p=0.0010), while there was no statistical difference in the doses of the 133 
contralateral breast (D1: 0.5 vs. 0.4 Gy, P=0.3112) and contralateral lung, (D1: 0.7 vs. 0.7 Gy, 134 
p=0.5345). 135 
In terms of the other OARs, dose to skin, ipsilateral lung and ribs were higher with CK 136 
than with BT: D1 was 20.6 Gy vs. 11.5 Gy (p=0.0018) to skin, 11.4 Gy vs. 9.6 Gy (p=0.0272) 137 
to ipsilateral lung and 18.5 Gy vs. 12.3 Gy (p=0.0013) to ribs, while D0.1 to heart for left sided 138 
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lesions was lower, 3.0 Gy vs. 3.2 Gy (p=0.0476), respectively. The detailed results can be found 139 
in Table 1. 140 
Discussion 141 
The debate on the advantages and disadvantages of different treatment techniques of 142 
APBI seems to be ongoing and refreshing when a new treatment modality appears. In spite of 143 
that several dosimetric and clinical comparative studies exist in the literature, no detailed 144 
analysis of the two most technologically advanced techniques, stereotactic CK and 145 
multicatheter HDR BT was performed yet. 146 
In our previous study we have pointed out that the 3D-CRT provides the best heart 147 
protection compared to step and shoot and sliding window IMRT and IMAT [8]. However, the 148 
sliding window IMRT technique achieved the best plan quality index and should be 149 
recommended for APBI. Goggin et al. [27] found that CK and 3D-CRT plans resulted in similar 150 
tumour coverage and dose to critical structures, with the exception of the lung V5%, which was 151 
significantly smaller for 3D-CRT than CK-Iris and CK-multi-leaf: 6.2% vs. 39.4% and 17.9%. 152 
Both CK plans demonstrated lower ipsilateral breast V50% (25.5% and 24.2%, respectively) 153 
than the 3D-CRT (56.2%). The CK plans were more conformal but less homogeneous. In the 154 
comparison of Xu et al [28] the PTV coverage from CK plans was the highest and the ratio of 155 
V20% to V100% of the breast was the smallest. The heart and lung doses were similar in CK, 156 
IMRT and 3D-CRT plans, except for the V5% of the lung and the heart, which was higher in 157 
CK plans. Rault et al. [29] found insignificant dosimetric differences between CK, 3D-CRT 158 
and IMRT plans regarding the PTV coverage and sparing the lung and heart. However, CK 159 
reduced high doses of the non-target breast. Bonfantini et al. [30] concluded that CK and IMAT 160 
provided higher conformity than 3D-CRT plans, although reduced the dose to the OARs. CK 161 
resulted in longer treatment times, but with it the delivery accuracy is expected to be better than 162 
with IMAT and 3D-CRT techniques. 163 
Khan et al. [31] stated that the dose coverage of the PTV was the highest with 164 
MammoSite balloon BT and the lowest using the 3D-CRT technique. Regarding sparing the 165 
ipsilateral breast, there were the same order between the studied techniques, but the mean dose 166 
of the ipsilateral lung was the lowest for IMRT and the highest for 3D-CRT, while in regard to 167 
volume of the heart irradiated by 5 Gy, IMRT yielded the lowest and MammoSite balloon 168 
resulted the highest value. The conflicting results published by different institutions most likely 169 
can be explained by differences in planning methods and the lack of standardized dosimetric 170 
parameters. 171 
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In our previous study it was shown that multicatheter HDR BT provided better sparing 172 
of normal tissue and OARs compared to IMRT [32]. Ipsilateral lung was spared better with BT, 173 
the mean lung dose was 5.1% vs. 7.1%, D1 was 39.0% vs. 54.3% and V5 was 32.9% vs. 41.7% 174 
in favour of BT. For left sided lesions the heart was generally irradiated by larger doses with 175 
BT. Mean heart dose was 4.5% vs. 2.0% and D2 was 18.3% vs. 19.7%, correspondingly. 176 
Volumetric maximal skin doses were similar, but regarding dose to 0.1 cm3 and 1 cm3 of most 177 
exposed volume, BT provided significantly less doses (76.6% vs. 94.4% and 60.2% vs. 87.8%, 178 
respectively). Ribs received less dose with BT with values of 45.6% vs. 69.3% for D1 and 1.4 179 
cm3 vs. 4.2 cm3 for V50. Dose to contralateral breast and lung was low with both techniques. 180 
No significant differences were observed in maximal doses, but dose to volumes of 0.1 cm3 and 181 
1 cm3 were less with BT for both organs. D1 was 3.2% vs. 6.7% for contralateral breast and 182 
3.7% vs. 5.6% for lung with BT and IMRT, respectively. In current study, we concluded the 183 
same result in term of stereotactic CK and HDR BT. However, the EQD2 total dose of the PTV 184 
was significantly lower with CK than with BT, D90 was 44.7 Gy and 49.0 Gy, BT yielded 185 
better sparing of OARs, except for the heart. V50 of the non-target breast was 10.5% and 3.3%, 186 
D1 to skin, ipsilateral lung and ribs were 35.2 Gy vs. 13.7 Gy, 14.0 Gy vs. 10.4 Gy and 28.7 Gy 187 
vs. 15.7 Gy, while D0.1 to heart was 2.4 Gy vs. 3.6 Gy for left-sided lesions in our CK and BT 188 
plans. Only, between doses of the contralateral breast and contralateral lung for the two 189 
techniques there was no significant difference, D1 was 0.3 Gy and 0.2 Gy to the contralateral 190 
breast and 0.5 Gy and 0.5 Gy to contralateral lung, respectively. 191 
Based on the radiobiological evaluation of Hoekstra et al. [33] about multicatheter HDR 192 
BT, 3D-CRT, CK, IMAT and WBI, WBI resulted in the highest risk with 4.3% excess risk of 193 
secondary cancer for patients at age 50 years. Lung cancers accounted for 75-97% of secondary 194 
malignancies. For a typical early stage patient irradiated at 50 years, the excess risks of 195 
secondary lung cancer were 1.1% for HDR BT, between 2.2% and 2.5% for 3D-CRT or CK, 196 
3.5% for IMAT APBI and 3.8% for WBI. This is in good agreement with our dosimetric results, 197 
where BT resulted in lower dose to lung than CK therapy. 198 
 It has to be mentioned, that in our study BT plans were made on the planning CT of the 199 
CK without template and real catheters, and the breast was not compressed. So this anatomy 200 
was disadvantageous for BT. On the other hand, the virtual needles were not parallel but we 201 
tried to mimic their real trajectories. In the light of our results multicatheter HDR BT proved to 202 
be the optimal choice in APBI in the aspects of sparing most of the OARs beside dose coverage 203 
of the PTV. Stereotactic CK therapy resulted in higher dose to the OARs at the equivalent 204 
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prescribed dose to the PTV. And even, our study comparing the dosimetrical parameters of 205 
plans treated by CK and HDR BT using two separate patient cohorts is in progress. 206 
Conclusions 207 
Using interstitial multicatheter HDR brachytherapy, D90 dose of the PTV is higher than with 208 
stereotactic CyberKnife radiotherapy, however CK technique results more conformal dose 209 
distributions. Dose to skin, ipsilateral lung and ribs is higher, while dose to heart is lower with 210 
CK than with HDR BT technique. There is no difference in the dose of the contralateral breast 211 
and -lung. Overall, multicatheter HDR brachytherapy yields more advantageous treatment 212 
plans in accelerated partial breast irradiation, except for the dose conformality and the dose to 213 
heart, where CK plans are more optimal. 214 
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Tables: 332 
 CK BT p* 
D90 
25.7 Gy (25.3-26.0) 
102.7% (101.3-105.2) 
27.0 Gy (26.7-27.9) 
108.1% (107.0-111.6) 
<0.001 
COIN 0.87 (0.77-0.92) 0.81 (0.77-0.85) 0.0030 
V50(non-target breast) 10.5% (5.0-17.0) 3.3% (0.9-8.1) 0.0010 
D1(contralat breast) 
0.5 Gy (0.1-1.5) 
2.2% (0.4-6.1) 
0.4 Gy (0.0-2.3) 
1.6% (0.0-9.3) 
0.3112 
D0.1(contralat breast) 
0.9 Gy (0.1-3.9) 
3.8% (0.3-15.5) 
0.6 Gy (0.0-2.9) 
2.5% (0.0-11.6) 
0.1205 
D1(skin) 
20.6 Gy (9.0-26.5) 
86.1% (52.4-106.0) 
11.5 Gy (5.2-21.5) 
46.1% (20.9-86.0) 
0.0018 
D0.1(skin) 
23.7 Gy (9.8-28.7) 
99.6% (70.2-114.6) 
15.2 Gy (8.4-27.3) 
60.9% (33.6-109.3) 
0.0203 
D1(ipsilat lung) 
11.4 Gy (0.9-16.9) 
45.0% (3.6-67.6) 
9.6 Gy (6.4-12.8) 
38.4% (25.6-51.2) 
0.0272 
D0.1(ipsilat lung) 
14.4 Gy (8.6-20.0) 
57.5% (34.2-80.0) 
10.9 Gy (7.6-14.5) 
43.8% (30.2-58.1) 
0.0008 
D1(contralat lung) 
0.7 Gy (0.1-2.5) 
2.9% (0.5-10.0) 
0.7 Gy (0.2-1.7) 
2.9% (0.8-6.8) 
0.5345 
D0.1(contralat lung) 
0.9 Gy (0.3-2.8) 
3.7% (1.3-11.2) 
1.0 Gy (0.4-2.1) 
4.0% (1.6-8.4) 
0.4671 
D1(heart) 
2.7 Gy (0.8-8.0) 
10.5% (3.2-32.0) 
2.8 Gy (0.1-5.7) 
11.2% (0.4-22.8) 
0.0534 
D0.1(heart) 
3.0 Gy (1.6-8.2) 
12.1% (6.4-32.8) 
3.2 Gy (0.1-8.5) 
12.8% (0.4-34.0) 
0.0476 
D1(ribs) 
18.5 Gy (10.9-24.7) 
73.6% (43.5-98.8) 
12.3 Gy (8.7-16.3) 
49.0% (34.9-65.1) 
0.0013 
D0.1(ribs) 
23.3 Gy (14.8-27.7) 
93.2% (59.3-110.6) 
15.3 Gy (9.9-20.3) 
61.2% (39.5-81.4) 
0.0012 
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Table 1. Mean total doses of CyberKnife (CK) and high-dose-rate brachytherapy (BT) of 333 
breast cancer. D90: the minimum dose delivered to 90% of the planning target volume, 334 
COIN: conformal index, V50(non-target breast): the relative volume of non-target breast 335 
receiving at least the 50% of the prescribed dose, D1(x) and D0.1(x): the minimal dose of 336 
the most exposed 1 and 0.1 cm3 of ‘x’ organ at risk, where x are contralateral breast 337 
(contralat breast), skin, ipsilateral lung (ipsilat lung), contralateral lung (contralat lung), 338 
heart and ribs. *Wilcoxon Matched Pairs Test. 339 
340 
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Figures: 341 
 342 
Figure 1. Axial CT slide (left) and 3D reconstruction (right) of a stereotactic CyberKnife 343 
breast radiotherapy (a,) and a multicatheter interstitial high-dose-rate breast 344 
brachytherapy (b,) plan. PTV: red, ipsilateral breast: yellow, contralateral breast: pink, 345 
spinal cord: green, ribs: white, heart: orange, ipsilateral lung: dark blue, contralateral 346 
lung: light blue. 347 
